A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC). (Q38392841)

From Wikidata

Jump to navigation Jump to search

scientific article published on 07 May 2016

Language	Label	Description	Also known as
English	A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).	scientific article published on 07 May 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC). (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

John D Hainsworth

1

object named as

John D Hainsworth

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

author name string

James A Reeves

2

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Joseph R Mace

3

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Edward J Crane

4

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Oday Hamid

5

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

John R Stille

6

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Amy Flynt

7

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Stephanie Roberson

8

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

John Polzer

9

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Edward R Arrowsmith

10

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

publication date

7 May 2016

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Targeted oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

643-653

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

CXCR4 and cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

The significance of cancer cell expression of the chemokine receptor CXCR4.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Akt activation, but not extracellular signal-regulated kinase activation, is required for SDF-1alpha/CXCR4-mediated migration of epitheloid carcinoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): From understanding the basics towards therapeutic targeting

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Emerging therapeutic approaches in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Agonists for the Chemokine Receptor CXCR4.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

CXCR4 signaling mediates morphine-induced tactile hyperalgesia.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

CXCR4 over-expression and survival in cancer: a system review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Role of VHL gene mutation in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11523-016-0434-9

21 January 2018

Silencing of CXCR4 blocks breast cancer metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27154357

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/27154357

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27154357

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11523-016-0434-9

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38392841&oldid=2201652302"